代表性成果（论文、专著、专利等） | 论文： Li W,Wu L,Jia H,Lin Z,Zhong R,Li Y,Jiang C,Liu S,Zhou X*,Zhang E*. The low-complexity domains of the KMT2D protein regulate histone monomethylation transcription to facilitate pancreatic cancer progression.Cellular & Molecular Biology Letters, 2021, 26: 45. Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi W, Sun Q, Zhang S, Hu J*, Xu H*. Recombination of a dual-CAR modified-T lymphocyte to accurate eliminate pancreatic malignancy. Journal of Hematology & Oncology, 2018, 11: 102. Zhang E, Gu J, Xue J, Lin C, Liu C, Li M, Hao J, Setrerrahmane S, Chi X, Qi W, Hu J*, Xu H*. Accurate control of dual receptor-engineered T cell activity through a bifunctional antiangiogenic peptide. Journal of Hematology & Oncology, 2018, 11: 44. Zhang E, Gu J, Xu H*. Prospects for chimeric antigen receptormodified T cell therapy for solid tumors. Molecular Cancer, 2018, 17: 7. Zhang E, Xu H. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. Journal of Hematology & Oncology, 2017, 10: 1.
课题： 中国博士后科学基金，新型CAR-T细胞分泌表达特异性融合蛋白HR改善肿瘤免疫抑制微环境及抗肿瘤的机制研究，2022M711722，2022.07-2024.06，主持，在研 南通市科技计划，新型靶向性融合蛋白HF促进CAR-T细胞精准治疗实体瘤的机制研究，JC12022091，2022.07-2024.06，主持，在研
3. 国家自然科学基金青年基金，双功能分子FPL1精准调控sdCAR-T细胞的抗肿瘤活性和机制研究，81903154，2020.01-2022.12，主持，结题 4. 南通市科技计划，基于PDL1抗体的新型分子调控CAR-T细胞抗肿瘤活性的机制研究，JC2019140，2019.07-2021.06，主持，结题 |
